Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study

Sponsor
Steno Diabetes Center Copenhagen (Other)
Overall Status
Completed
CT.gov ID
NCT04089462
Collaborator
(none)
26
1
2
15.1
1.7

Study Details

Study Description

Brief Summary

According to the Standards of Medical Care in Diabetes by the American Diabetes Association, people with diabetes should aim for 30 minutes of moderate-to-vigorous intensity aerobic exercise at least 5 days a week or a total of 150 minutes per week and doing some type of strength training at least 2 times per week in addition to aerobic activity. However, the effects of different forms and intervals of exercise on glycemic control are not well established. Exercise increases the risk of hypoglycemia both during and several hours after exercise.

There are several strategies to avoid hypoglycemia during exercise. The most common strategy is to reduce insulin and to take carbohydrates before the exercise starts. Short-acting insulin analogs have a duration of approximately four hours, thus reductions need to be planned and done well in advance before the exercise starts. Since different types of exercise (aerobic, strength training or high intensity training) affect blood glucose in different ways and most exercise sessions include a combination of the types, these strategies are often associated with difficulties in obtaining stable blood glucose. The American Diabetes Association guidelines do not explicitly recommend a daily workout routine but outline recommendations for weekly amounts of exercise as there is currently insufficient evidence on the ideal timing, frequency and duration of exercise for preventing hypoglycemia.

Hypothesis: in people with type 1 diabetes, time in hypoglycemia can be reduced if exercise is performed daily over five consecutive days compared to the same total amount of exercise performed at 2 days with at least 2 days interval.

Aim: to evaluate the impact of the same total amount of exercise split into either five consecutive sessions or two sessions with at least 2 days in between on percentage of time spent in hypoglycemia and other glycemic parameters in people with type 1 diabetes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: "Five sessions per period" - "Two sessions per period"
  • Behavioral: "Two sessions per period" - "Five sessions per period"
N/A

Detailed Description

The participants will go through two interventions: Exercise one session per day for five consecutive days and Exercise one session per day for two days within five days. The exercise session will start with anaerobic (push-ups, back-curls, sit-ups, triceps-dips and jumps) exercise followed by aerobic exercise (moderate intensity of running, walking or cycling). Between the two intervention periods, there will be a wash-out period.

Intervention: 'Exercise one session per day for five consecutive days'. Duration per session:

Anaerobic: 4 min, Aerobic: 30 min. Sessions per intervention period: Five. Total duration per intervention period: Anaerobic: 20 min. Aerobic: 150 min. Total: 170 min

Intervention:Exercise one session per day for two days within five days. Duration per session: Anaerobe: 10 min, Aerobe: 75 min. Sessions per intervention period: 2. Total duration per intervention period: Anaerob: 20 min Aerobe: 150 min Total: 170 min

Study Design

Study Type:
Interventional
Actual Enrollment :
26 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
An open-labelled randomized controlled crossover study will be performed. The participants will go through the following elements: Screening day Run-in period Intervention period Wash-out period Intervention periodAn open-labelled randomized controlled crossover study will be performed. The participants will go through the following elements:Screening day Run-in period Intervention period Wash-out period Intervention period
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes - A Randomized Crossover Study
Actual Study Start Date :
Sep 30, 2019
Actual Primary Completion Date :
Oct 15, 2020
Actual Study Completion Date :
Jan 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Other: 1. "Five sessions per period" - "Two sessions per period"

Behavioral: "Five sessions per period" - "Two sessions per period"
Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session) Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)

Other: 2. "Two sessions per period" - "Five sessions per period"

Behavioral: "Two sessions per period" - "Five sessions per period"
Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session) Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)

Outcome Measures

Primary Outcome Measures

  1. Percentage of time spent in the hypoglycemic range (CGM <3.9 mmol/l) [The primary intervention period from 06:00h study day 1 - 06:00h study day 6 (ITT)]

    Intention-to-treat analysis (ITT).

Secondary Outcome Measures

  1. Percentage of time spent in the hypoglycemic range (CGM <3.9 mmol/l) [Primary intervention period from 06:00h study day 1 - 06:00h study day 6 PP]

    Per protocol analysis (PP)

  2. Percentage of time spent in the alert and clinical hypoglycemic range [Study day 1: The day when the first exercise session is performed and registered.]

    Level 1 (alert): CGM or SMBG value of 3.0-3.9 mmol/l with or without symptoms. Level 2 (clinical): CGM or SMBG value of < 3.0 mmol/l with or without symptoms. Outcome is compared between the two intervention periods in a per protocol analysis (PP) and intention-to-treat analysis (ITT)

  3. Percentage of time spent in the alert and clinical hypoglycemic range [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Level 1 (alert): CGM or SMBG value of 3.0-3.9 mmol/l with or without symptoms. Level 2 (clinical): CGM or SMBG value of < 3.0 mmol/l with or without symptoms. Outcome is also compared between the two intervention periods in a per protocol analysis (PP) and intention-to-treat analysis (ITT)

  4. Percentage of time spent in the alert and clinical hypoglycemic range [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Level 1 (alert): CGM or SMBG value of 3.0-3.9 mmol/l with or without symptoms. Level 2 (clinical): CGM or SMBG value of < 3.0 mmol/l with or without symptoms. Outcome is also compared between the two intervention periods in a per protocol analysis (PP) and intention-to-treat analysis (ITT)

  5. Percentage of time spent in the alert and clinical hypoglycemic range [Day time: 06:00-22:00h from during study day 1 to study day 6.]

    Level 1 (alert): CGM or SMBG value of 3.0-3.9 mmol/l with or without symptoms. Level 2 (clinical): CGM or SMBG value of < 3.0 mmol/l with or without symptoms. Outcome is also compared between the two intervention periods in a per protocol analysis (PP) and intention-to-treat analysis (ITT)

  6. Percentage of time spent in the alert and clinical hypoglycemic range [Night time: 22:00-06:00h from during study day 1 to study day 6.]

    Level 1 (alert): CGM or SMBG value of 3.0-3.9 mmol/l with or without symptoms. Level 2 (clinical): CGM or SMBG value of < 3.0 mmol/l with or without symptoms. Outcome is compared between the two intervention periods in a per protocol analysis (PP) and intention-to-treat analysis (ITT)

  7. Percentage of time spent in the alert and clinical hypoglycemic range [The time the participant has recorded start and end of exercise session during study day 1 to study day 6]

    Level 1 (alert): CGM or SMBG value of 3.0-3.9 mmol/l with or without symptoms. Level 2 (clinical): CGM or SMBG value of < 3.0 mmol/l with or without symptoms. Outcome is compared between the two intervention periods in a per protocol analysis (PP) and intention-to-treat analysis (ITT)

  8. Number of alert and clinical hypoglycemia events [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  9. Number of alert and clinical hypoglycemia events [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  10. Number of alert and clinical hypoglycemia events [Day time: 06:00-22:00h during study day 1 - study day 6]

    Per protocol analysis and intention-to-treat analysis

  11. Number of alert and clinical hypoglycemia events [Night time: 22:00-06:00h during study day 1 - study day 6]

    Per protocol analysis and intention-to-treat analysis

  12. Number of alert and clinical hypoglycemia events [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 study day 6]

    Per protocol analysis and intention-to-treat analysis

  13. Number of severe hypoglycemia events during [Study day 1: The day when the first exercise session is performed and registered]

    Per protocol analysis and intention-to-treat analysis

  14. Number of severe hypoglycemia events [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  15. Number of severe hypoglycemia events [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  16. Number of severe hypoglycemia events [Day time: 06:00-22:00h during study day 1 - study day 6]

    Per protocol analysis and intention-to-treat analysis

  17. Number of severe hypoglycemia events [Night time: 22:00-06:00h during study day 1 - study day 6]

    Per protocol analysis and intention-to-treat analysis

  18. Number of severe hypoglycemia events [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 - study day 6]

    Per protocol analysis and intention-to-treat analysis

  19. Percentage of time in range (3.9-10 mmol/l) [Study day 1: The day when the first exercise session is performed and registered]

    Per protocol analysis and intention-to-treat analysis

  20. Percentage of time in range (3.9-10 mmol/l) [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  21. Percentage of time in range (3.9-10 mmol/l) [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  22. Percentage of time in range (3.9-10 mmol/l) [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  23. Percentage of time in range (3.9-10 mmol/l) [Night time: 22:00-06:00h during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  24. Percentage of time in range (3.9-10 mmol/l) [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  25. Percentage of time in good range (3.9-7.8 mmol/l) [Study day 1: The day when the first exercise session is performed and registered.]

    Per protocol analysis and intention-to-treat analysis

  26. Percentage of time in good range (3.9-7.8 mmol/l) [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  27. Percentage of time in good range (3.9-7.8 mmol/l) [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  28. Percentage of time in good range (3.9-7.8 mmol/l) [Day time: 06:00-22:00h and Night time: 22:00-06:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  29. Percentage of time in good range (3.9-7.8 mmol/l) [Exercise time: The time the participant has recorded start and end of exercise session during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  30. Percentage of time in hyperglycemia (>10 mmol/l) [Study day 1: The day when the first exercise session is performed and registered.]

    Per protocol analysis and intention-to-treat analysis

  31. Percentage of time in hyperglycemia (>10 mmol/l) [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  32. Percentage of time in hyperglycemia (>10 mmol/l) [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  33. Percentage of time in hyperglycemia (>10 mmol/l) [Night time: 22:00-06:00h during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  34. Percentage of time in hyperglycemia (>10 mmol/l) [Exercise time: The time the participant has recorded start and end of exercise session during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  35. Percentage of time in hyperglycemia (>10 mmol/l) during all the predefined time blocks. Per protocol analysis and intention-to-treat analysis [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  36. Glycemic variability measured as standard deviation (SD), coefficient of variation (CV) and low and high blood glucose index (LBGI/HBGI) during all the predefined time blocks in the intervention period [Study day 1: The day when the first exercise session is performed and registered.]

    Per protocol analysis and intention-to-treat analysis

  37. Glycemic variability measured as standard deviation (SD), coefficient of variation (CV) and low and high blood glucose index (LBGI/HBGI) during all the predefined time blocks in the intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  38. Glycemic variability measured as standard deviation (SD), coefficient of variation (CV) and low and high blood glucose index (LBGI/HBGI) during all the predefined time blocks in the intervention period [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  39. Glycemic variability measured as standard deviation (SD), coefficient of variation (CV) and low and high blood glucose index (LBGI/HBGI) during all the predefined time blocks in the intervention period [Night time: 22:00-06:00h during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  40. Glycemic variability measured as standard deviation (SD), coefficient of variation (CV) and low and high blood glucose index (LBGI/HBGI) during all the predefined time blocks in the intervention period [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  41. Mean CGM glucose level du during all the predefined time blocks in the intervention period [Study day 1: The day when the first exercise session is performed and registered.]

    Per protocol analysis and intention-to-treat analysis

  42. Mean CGM glucose level du during all the predefined time blocks in the intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  43. Mean CGM glucose level du during all the predefined time blocks in the intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  44. Mean CGM glucose level du during all the predefined time blocks in the intervention period [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  45. Mean CGM glucose level du during all the predefined time blocks in the intervention period [Night time: 22:00-06:00h during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  46. Mean CGM glucose level du during all the predefined time blocks in the intervention period [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  47. CGM estimated eA1c during the primary intervention period [The Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  48. Total carbohydrate intake registered from the insulin pumps during all the predefined time blocks in the intervention period [Study day 1: The day when the first exercise session is performed and registered.]

    Per protocol analysis and intention-to-treat analysis

  49. Total carbohydrate intake registered from the insulin pumps during all the predefined time blocks in the intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  50. Total carbohydrate intake registered from the insulin pumps during all the predefined time blocks in the intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  51. Total carbohydrate intake registered from the insulin pumps during all the predefined time blocks in the intervention period [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  52. Total carbohydrate intake registered from the insulin pumps during all the predefined time blocks in the intervention period [Night time: 22:00-06:00h during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  53. Total carbohydrate intake registered from the insulin pumps during all the predefined time blocks in the intervention period [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  54. Carbohydrate interventions for prevention and treatment of hypoglycemia registered by the participants in the booklet for the primary and total intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis c) Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).

  55. Carbohydrate interventions for prevention and treatment of hypoglycemia registered by the participants in the booklet for the primary and total intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis c) Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).

  56. Change in total daily insulin dose (basal and bolus insulin) of 7 days prior to screening day and during the primary and total intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  57. Change in total daily insulin dose (basal and bolus insulin) of 7 days prior to screening day and during the primary and total intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  58. Actigraph wrist wear time during all predefined time blocks [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  59. Actigraph wrist wear time during all predefined time blocks [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  60. Actigraph wrist wear time during all predefined time blocks [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  61. Actigraph wrist wear time during all predefined time blocks [Night time: 22:00-06:00h during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  62. Actigraph wrist wear time during all predefined time blocks [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  63. Physical activity energy expenditure (accelerometer and heart rate based) measured as kcal during all predefined time blocks [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  64. Physical activity energy expenditure (accelerometer and heart rate based) measured as kcal during all predefined time blocks [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  65. Physical activity energy expenditure (accelerometer and heart rate based) measured as kcal during all predefined time blocks [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  66. Physical activity energy expenditure (accelerometer and heart rate based) measured as kcal during all predefined time blocks [Night time: 22:00-06:00h during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  67. Physical activity energy expenditure (accelerometer and heart rate based) measured as kcal during all predefined time blocks [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  68. Metabolic expenditure rate for the primary intervention periods [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  69. Metabolic expenditure rate for the primary intervention periods [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  70. Number of exercise (light to vigorous) and sedentary bouts in the primary intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  71. Number of exercise (light to vigorous) and sedentary bouts in the primary intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  72. Time in sedentary during predefined time blocks [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  73. Time in sedentary during predefined time blocks [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  74. Time in sedentary during predefined time blocks [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  75. Time in sedentary during predefined time blocks [Night time: 22:00-06:00h during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  76. Time in sedentary during predefined time blocks [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  77. Time in light physical activity during predefined time blocks [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  78. Time in light physical activity during predefined time blocks [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  79. Time in light physical activity during predefined time blocks [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  80. Time in light physical activity during predefined time blocks [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  81. Time in moderate physical activity during predefined time blocks [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  82. Time in moderate physical activity during predefined time blocks [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days).]

    Per protocol analysis and intention-to-treat analysis

  83. Time in moderate physical activity during predefined time blocks [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  84. Time in moderate physical activity during predefined time blocks [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  85. Time in vigorous physical activity during predefined time blocks [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  86. Time in vigorous physical activity during predefined time blocks [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  87. Time in vigorous physical activity during predefined time blocks [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  88. Time in vigorous physical activity during predefined time blocks [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  89. Number of steps during predefined time blocks [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  90. Number of steps during predefined time blocks [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  91. Number of steps during predefined time blocks [Day time: 06:00-22:00h during study day 1-study day 6]

    Per protocol analysis and intention-to-treat analysis

  92. Number of steps during predefined time blocks [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  93. Heart rate during exercise sessions [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  94. R-R intervals during exercise sessions (f) [Exercise time: The time the participant has recorded start and end of exercise session during study day 1 -study day 6]

    Per protocol analysis and intention-to-treat analysis

  95. Sleep latency (min) during the primary and total intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  96. Sleep latency (min) during the primary and total intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  97. Total sleep time (min) during the primary and total intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  98. Total sleep time (min) during the primary and total intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  99. Sleep efficiency (%) during the primary and total intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  100. Sleep efficiency (%) during the primary and total intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  101. Number of awakening during sleep in the primary and total intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  102. Number of awakening during sleep in the primary and total intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  103. Time of awakening during sleep in the primary and total intervention period [Primary intervention period: 06:00h study day 1 - 06:00h study day 6 (= 5 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  104. Time of awakening during sleep in the primary and total intervention period [Secondary intervention period: 08:00h day 1 - 08:00h day 8 (= 7 x 24-hour days)]

    Per protocol analysis and intention-to-treat analysis

  105. Question about patient preference regarding the two study arms [At the end of study. Study day 6 the last interventions period.]

    Per protocol analysis and intention-to-treat analysis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Type 1 Diabetes ≥ 2 year

  • Insulin pump ≥ 1 year.

  • Use of carbohydrate counting and the insulin pump bolus calculator for all meals

Exclusion Criteria:
  • Use of anti-diabetic medicine (other than insulin), per oral or injected corticosteroids or other drugs affecting glucose metabolism during the intervention period or within 30 days prior to study start

  • Known or suspected alcohol or drug abuse

  • Other concomitant medical or psychological condition that according to the investigator's assessment makes the participant unsuitable for study participation

  • Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods

  • Inability to understand the participants' information and to give informed consent

  • Chronic use or unable to stop acetaminophen (paracetamol) use

  • Allergy to the patch of CGM

  • Hypoglycemia unawareness, quantified by Pedersen-Bjergaard

  • Severe hypoglycemia within the last year

  • Vigorous-intensity exercise for more than 60 minutes on 3 days or more per week

Contacts and Locations

Locations

Site City State Country Postal Code
1 Steno Diabetes Center Copenhagen Gentofte Denmark 2820

Sponsors and Collaborators

  • Steno Diabetes Center Copenhagen

Investigators

  • Principal Investigator: Isabelle IK Steineck, MD, Steno Diabetes Center Copenhagen

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Steno Diabetes Center Copenhagen
ClinicalTrials.gov Identifier:
NCT04089462
Other Study ID Numbers:
  • H-19035830
First Posted:
Sep 13, 2019
Last Update Posted:
Sep 28, 2021
Last Verified:
Jun 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Steno Diabetes Center Copenhagen
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 28, 2021